Literature DB >> 15968935

Seizure worsening caused by decreased serum valproate during meropenem therapy.

Margherita Santucci1, Antonia Parmeggiani, Roberta Riva.   

Abstract

Serum concentrations of valproate were reduced and seizures were exacerbated by concomitant meropenem therapy in a child with a neurodegenerative disorder and epilepsy. In this patient, a rapid decline of valproate serum concentrations was observed on two occasions with meropenem antibiotic therapy. This event was the most likely cause of observed seizure exacerbation. Meropenem should be used with caution in patients treated with valproate owing to the drastic lowering of serum valproate concentration and the consequent risk of seizure worsening.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968935     DOI: 10.1177/08830738050200051401

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors:  Duane Bates; Michael Parkins; Keltie Duggan
Journal:  Can J Hosp Pharm       Date:  2010-07

2.  Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications.

Authors:  Carla Carnovale; Marco Pozzi; Faizan Mazhar; Giulia Mosini; Marta Gentili; Gabriëlla G A M Peeters; Emilio Clementi; Sonia Radice
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 3.  Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.

Authors:  Peter Linden
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.